Popular Articles
Stretch Mark Cream

CEL-SCI Files Patent Application To Support Company's Treatment For More Virulent Strain Of H1N1 Swine And Other Influenza Viruses
CEL-SCI CORPORATION (NYSE AMEX: CVM) announced that it has filed a provisional U.S. patent application covering its L.E.A.P.S.(TM) immune therapy drugs (vaccines) for the prevention/treatment of H1N1, swine, bird flu, Influenza A and/or evolving mutants or variants of these viruses. Some experts believe that by the next flu season the swine flu virus will have evolved and/or combined with other viruses to create a much more lethal new virus. That is what happened in the case of the Spanish flu pandemic. CEL-SCI"s efforts to fight this virus are focused on using conserved epitopes from essential proteins to be found in the A influenza virus for H1N1, H1N5, swine, bird flu and Spanish influenza to create an effective vaccine/treatment that could potentially fight such a mutant virus.
generic viagra online
Merck Issues Statement On WHO Study Showing First Evidence That Elimination Of River Blindness Is Feasible In Africa
Merck & Co., Inc. issued the following statement in response to study results published today by the World Health Organization offering the first evidence that elimination of the tropical disease river blindness (onchocerciasis) in Africa is feasible with treatment with ivermectin (registered trademark Mectizan®). As the discoverer and manufacturer of Mectizan, Merck decided in 1987 to donate the drug to all who need it for as long as necessary until river blindness is eliminated as a public health problem. The Merck Mectizan Donation Program is one of the longest-running disease-specific drug donation and public/private partnership programs in history. Purchase zoloft to treat depression.
News of the day
Abrupt Opioid Withdrawal Increases Pain Sensitivity
The abrupt withdrawal of morphine-like analgesics - opioids - can
Diagnostics

Among Men Living With Early, Untreated Prostate Cancer, Study Finds Acceptable Levels Of Anxiety

Men with early stages of prostate cancer who delay radical treatment in favor of an approach of "expectant management" do not have high levels of anxiety and distress. That is the conclusion of a new study published in the September 1, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society. The study"s results suggest that living with untreated cancer is not upsetting for many patients with early prostate cancer. The rapid increase in the use of screening using prostate specific antigen (PSA) testing has led to a large number of men diagnosed with prostate cancer, many of who do not require treatment. In these cases, close clinical monitoring - or active surveillance - is often recommended. If progression of the cancer occurs during active surveillance, patients may undergo radical therapy. While active surveillance may delay or even avoid the possible adverse side effects of radical treatment, it could also cause psychological harm in patients because they must live with untreated cancer. Data on the levels of such potentially negative emotions among men on active surveillance are lacking, however. Roderick van den Bergh, (MD), of the Erasmus Medical Center, in Rotterdam, the Netherlands, and colleagues assessed levels of anxiety and distress in a group of recently diagnosed prostate cancer patients on active surveillance. They sent 150 men questionnaires to gauge uncertainty about their treatment decision, as well as levels of depression and anxiety among these men. A total of 129 questionnaires were completed and returned an average of 2.7 months after diagnosis. More than 80 percent of the 129 respondents scored favorably low on the parameters measured. Patients" scores were comparable or favorable to scores of men (reported in other studies) who underwent treatment for early prostate cancer. Certain men in the study - such as men with neurotic personalities and those who were in poor physical health - exhibited more anxiety and distress than others. These findings indicate that besides cancer-specific factors, mental and physical patient-specific factors are important aspects to take into account when selecting men for active surveillance. The results also suggest that psychological support may be indicated in certain patients undergoing active surveillance. While this study"s findings are useful, Dr. van den Bergh noted that longer-term analyses are needed on the psychological effects of active surveillance in men with early prostate cancer. His research team is currently conducting such a study. Article: "Anxiety and distress during active surveillance for early prostate cancer." Roderick C.N. van den Bergh, Marie-Louise Essink-Bot, Monique J. Roobol, Tineke Wolters, Fritz H. Schrç¶der, Chris H. Bangma, and Ewout W. Steyerberg. Cancer; Published Online: July 27, 2009 (DOI: 10.1002/cncr.24446); Print Issue Date: September 1, 2009. David Sampson American Cancer Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):